The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
7th European CAR T-cell Meeting congress coverage
Stay up to date with the latest developments in multiple myeloma with our live social media coverage from the 7th European CAR T-cell Meeting, February 6–8, 2025, Strasbourg, FR.
CONGRESS | #CART25 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) February 8, 2025
Niels van de Donk @amsterdamumc provides an overview of bispecific antibody therapies for patients with multiple myeloma. They present results from several key studies and discuss potential future directions.#myeloma #mmsm #MedicalCongress pic.twitter.com/piGjqf3vsU
CONGRESS | #CART25 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) February 8, 2025
Vladan Vucinic @UniLeipzig discusses results from several real-world studies of commercial CAR T-cell therapies for the treatment of patients with multiple myeloma. They highlight factors associated with outcomes, and raise the need for clinical… pic.twitter.com/XW41w0HN16
CONGRESS | #CART25 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) February 8, 2025
Carlos Fernández de Larrea @fdezdelarrea @hospitalclinic highlights results from a study of ARI0002h in patients with R/R multiple myeloma, and discusses the potential impact of academic point-of-care CAR T-cell manufacturing on access to CAR… pic.twitter.com/WAoC5w0Psf
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
